Literature DB >> 7264368

Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections.

H A Verbrugh, R Peters, M Rozenberg-Arska, P K Peterson, J Verhoef.   

Abstract

An enzyme-linked immunoassay was used to detect antibodies to the cell wall peptidoglycan of Staphylococcus aureus in human sera. All 170 sera from donors and patients with staphylococcal and nonstaphylococcal infections contained IgG antibodies to peptidoglycan; antibody levels varied with age, and transplacental transfer occurred. IgM antibodies to peptidoglycan were not found in donors and were present in only one patient with serious staphylococcal infection. Significantly elevated levels of IgG antibodies to peptidoglycan were observed in 20 (80%) of 25 patients with deep tissue infection with S. aureus but in only two (9%) of 22 patients with superficial staphylococcal infection. An increase in levels of antibodies to peptidoglycan generally coincided with an increase in level of IgG antibodies to teichoic acid. No cross-reactivity between peptidoglycan and teichoic acid was observed. Thus, staphylococcal peptidoglycan is immunogenic in humans, and testing for IgG antibodies to peptidoglycan may be useful in the diagnosis and follow-up of serious staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264368     DOI: 10.1093/infdis/144.1.1

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Humoral immune responses in osteomyelitis.

Authors:  V P Bansal; P K Mittal; G Ashokraj
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

2.  Antibody response to teichoic acid and peptidoglycan in Staphylococcus aureus osteomyelitis.

Authors:  E Jacob; L C Durham; M C Falk; T J Williams; L J Wheat
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

3.  Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis.

Authors:  Dawei Sun; Brent Raisley; Marybeth Langer; Janaki K Iyer; Vidya Vedham; Jimmy L Ballard; Judith A James; Jordan Metcalf; K Mark Coggeshall
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

4.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

5.  Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.

Authors:  M B Marques; D L Kasper; A Shroff; F Michon; H J Jennings; M R Wessels
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Enzyme-linked immunosorbent assay for antibodies against teichoic acid in patients with staphylococcal infections.

Authors:  M Granström; I G Julander; S A Hedström; R Möllby
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

7.  Comparison of a new enzyme-linked immunosorbent assay method with counterimmunoelectrophoresis for detection of teichoic acid antibodies in sera from patients with Staphylococcus aureus infections.

Authors:  C Herzog; H C Wood; I Noel; J C Booth
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

8.  Detection of anti-teichoic acid immunoglobulin G antibodies in experimental Staphylococcus epidermidis endocarditis.

Authors:  T E West; J R Cantey; M A Apicella; N M Burdash
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

9.  Oral cefuroxime axetil compared with oral ampicillin in treating acute uncomplicated gonorrhoea.

Authors:  T M Wanas; P E Williams
Journal:  Genitourin Med       Date:  1986-08

10.  Antibodies to a range of Staphylococcus aureus and Escherichia coli heat shock proteins in sera from patients with S. aureus endocarditis.

Authors:  M W Qoronfleh; W Weraarchakul; B J Wilkinson
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.